Svetlana Lucas
Director/Board Member chez ATYR PHARMA, INC.
Fortune : 11 700 $ au 31/03/2024
Profil
Dr. Svetlana Lucas is an Independent Director at aTyr Pharma, Inc. and a Chief Business Officer at Scribe Therapeutics, Inc. She is on the Board of Directors at aTyr Pharma, Inc. Dr. Lucas was previously employed as a Senior Vice President-Business Development by Tizona Therapeutics, Inc. and a Head-Oncology & Inflammation by Amgen, Inc. She received her undergraduate degree from Moscow State University Lomonosov and a doctorate degree from California Institute of Technology.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
ATYR PHARMA, INC.
0,01% | 01/03/2024 | 6 000 ( 0,01% ) | 11 700 $ | 31/03/2024 |
Postes actifs de Svetlana Lucas
Sociétés | Poste | Début |
---|---|---|
ATYR PHARMA, INC. | Director/Board Member | 28/06/2019 |
Scribe Therapeutics, Inc.
Scribe Therapeutics, Inc. BiotechnologyHealth Technology Scribe Therapeutics, Inc. engages in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Berkeley, CA. | Corporate Officer/Principal | - |
Anciens postes connus de Svetlana Lucas
Sociétés | Poste | Fin |
---|---|---|
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/06/2019 |
AMGEN INC. | Corporate Officer/Principal | 01/07/2015 |
Formation de Svetlana Lucas
California Institute of Technology | Doctorate Degree |
Moscow State University Lomonosov | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
AMGEN INC. | Health Technology |
ATYR PHARMA, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Health Technology |
Scribe Therapeutics, Inc.
Scribe Therapeutics, Inc. BiotechnologyHealth Technology Scribe Therapeutics, Inc. engages in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Berkeley, CA. | Health Technology |